SCHEMBL1077149

SCHEMBL1077149

CCOC(CC)(CC)C(O)CO

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3139423 0.78
SCHEMBL9165611 0.75 TSHR (0.31) TSHRTDP1
SCHEMBL27575640 0.75 TSHR (0.31) TSHRTDP1
SCHEMBL27541974 0.73
SCHEMBL18973983 0.69 TSHR (0.31) TSHR
SCHEMBL18973954 0.69 TSHR (0.31) TSHR
SCHEMBL27551463 0.69 USP2 (0.33)
SCHEMBL3084592 0.68 TSHR (0.30) TSHR
SCHEMBL27394581 0.67 ALDH1A1 (0.31)
SCHEMBL28343870 0.67 TDP1 (0.37) TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238251-A9 A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2024-07-18 US claimed
WO-2024146964-A1 METHOD OF PREPARING MICROPARTICLES, PHARMACEUTICAL POLYMERIC COMPOSITIONS, ACTIVE INGREDIENT DELIVERY MEDICAL DEVICE AND IMPLANT BODMEIER ROLAND (DE) 2024-07-11 WO claimed
US-20230404909-A1 MICRONEEDLE PATCH FOR DELIVERING AN ACTIVE INGREDIENT TO SKIN LEO PHARMA AS (DK) 2023-12-21 US claimed
US-20230390245-A1 A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof SHANGHAI YASHENG PHARMACEUTICAL TECH CO LTD (CN) 2023-12-07 US claimed
CN-116799213-A Lithium ion battery positive electrode slurry dispersion auxiliary agent and preparation method and application thereof 江西安驰新能源科技有限公司 2023-09-22 CN claimed
EP-4240330-A1 A COMPOSITION COMPRISING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD AND APPLICATION THEREOF Shanghai Yasheng Pharmaceutical Technology Co., Ltd. (CN) 2023-09-13 EP claimed
WO-2022095894-A1 A COMPOSITION COMPRISING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD AND APPLICATION THEREOF Shanghai Yasheng Pharmaceutical Technology Co., Ltd. (CN) 2022-05-12 WO claimed
CN-113842376-A Risperidone-containing pharmaceutical composition, oral dissolving film agent and preparation method 齐鲁制药有限公司 2021-12-28 CN claimed
CN-107405301-B Microneedle patch for delivering active ingredients to the skin 利奥制药有限公司 2021-11-30 CN claimed
EP-3273942-B1 MICRONEEDLE PATCH FOR DELIVERING AN ACTIVE INGREDIENT TO THE SKIN LEO PHARMA AS (DK) 2021-06-16 EP claimed
WO-2004011054-A2 INJECTABLE MULTIMODAL POLYMER DEPOT COMPOSITIONS AND USES THEREOF ALZA CORPORATION (US) 2004-02-05 WO claimed
US-6673767-B1 DRUG DELIVERY USING TIME-RELEASE AGENTS COMPRISINGS POLYLACTIC ACID, PLASTICIZER SOLVENTS SELECTED FROM BENZYL OR ETHYL BENZOATE AND CDNA, DNA, PROTEINS, PEPTIDES AND/OR ANTICARCINOGENIC AGENTS ALZA CORPORATION 2004-01-06 US claimed
US-20030211974-A1 Gel composition and methods DURECT CORPORATION 2003-11-13 US claimed
US-20030044467-A1 Gel composition and methods DURECT CORPORATION 2003-03-06 US claimed
US-6468961-B1 IMPLANTABLE COMPOSITION FOR SUSTAINED DELIVERY OF BENEFICIAL AGENT COMPRISING POLYLACTIDE POLYMER, AMOUNT OF SOLVENT COMPRISING LOWER ALKYL OR ARALKYL ESTER OF BENZOIC ACID EFFECTIVE TO FORM VISCOUS GEL, BENEFICIAL AGENT ALZA CORPORATION 2002-10-22 US claimed
US-6130200-A Gel composition and methods ALZA CORPORATION (US) 2000-10-10 US claimed
EP-0959873-A2 GEL COMPOSITION AND METHODS ALZA CORPORATION (US) 1999-12-01 EP claimed
WO-1998027963-A2 GEL COMPOSITION AND METHODS ALZA CORPORATION (US) 1998-07-02 WO claimed
US-5705196-A Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles LABORATORIOS CUSI, S.A. (ES) 1998-01-06 US claimed
US-H1565-H Superabsorbent, continuous filament web DEUTSCHE BANK AG, NEW YORK BRANCH 1996-07-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230390245-A1 A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof ABCG2, AP1G1, ALPI TSHR 3673/4885TDP1 3996/4885
US-20230404909-A1 MICRONEEDLE PATCH FOR DELIVERING AN ACTIVE INGREDIENT TO SKIN MMP1, MMP17, CUTA TSHR 4023/4885TDP1 2657/4885
US-20030211974-A1 Gel composition and methods CXCL8, MMP1, BMP2 TSHR 4201/4885TDP1 1301/4885
US-20240238251-A9 A Composition Comprising Heterocyclic Compounds, Preparation Method and Application Thereof ABCG2, AP1G1, ALPI TSHR 3673/4885TDP1 3996/4885
US-20030044467-A1 Gel composition and methods CXCL8, MMP1, BMP2 TSHR 4201/4885TDP1 1301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.